Tilray Brands is ramping up its global medical cannabis production with expanded cultivation operations in Quebec and Portugal, part of a broader push by Canadian licensed producers to capture market share in Europe's growing medical cannabis sector.
The company's expansion comes as European nations continue loosening medical cannabis regulations, creating new opportunities for established North American producers with existing EU footholds. Tilray operates cultivation facilities through its subsidiary in Portugal, a strategic gateway to European markets.
Canadian LPs have maintained a presence in Europe since the early days of legalization, but recent regulatory changes across the continent have accelerated investment. Germany's medical cannabis market alone has grown substantially since liberalizing access rules, while countries like Poland and the Czech Republic have expanded their programs.
The European Play
Tilray's dual-continent approach reflects a common strategy among Canadian producers: maintain domestic capacity while establishing European operations to serve local markets and avoid import restrictions. Portugal has emerged as a preferred location for cultivation due to its climate, lower operating costs, and position within the European Union's regulatory framework.
The Quebec expansion suggests Tilray is also preparing for increased exports under Canada's medical cannabis export program, which has seen growing volumes shipped to European partners in recent years. Health Canada data shows Canadian medical cannabis exports reached new highs in 2023, with Europe representing the largest destination market.
Other major Canadian LPs including Aurora Cannabis and Organigram have similarly invested in European operations or export agreements. The continent's medical-only framework appeals to producers facing oversupply and price compression in recreational markets back home.
Market Dynamics
European medical cannabis sales are projected to grow significantly through 2028, driven by patient enrollment increases and new country programs. Germany's recent move toward recreational legalization—albeit limited—has further validated the market's long-term potential.
But the European opportunity comes with challenges. Each country maintains distinct regulatory requirements, import procedures, and product standards. Reimbursement policies vary widely, affecting patient access and market size. Some markets remain restricted to domestic production, limiting export opportunities.
Canadian producers also face competition from European-based cultivators and pharmaceutical companies entering the space. Israel, another major cannabis exporter, has positioned itself as an alternative supplier to EU markets.
What's Next
Tilray has not disclosed specific capacity targets for the Quebec and Portugal expansions or investment amounts. The company reports medical cannabis sales across multiple international markets, though it does not break out European revenue separately in quarterly filings.
The expansion timing aligns with Tilray's broader international strategy, which includes recent moves in the UK market and continued operations in Australia and New Zealand. CEO Irwin Simon has previously emphasized medical cannabis and international markets as key growth drivers as the company works to achieve profitability.
Industry observers expect more Canadian LPs to announce European investments as the regulatory environment continues evolving. Poland's medical program expansion and potential new markets in Eastern Europe represent the next frontier for North American producers seeking international revenue.
This article is based on original reporting by mjbizdaily.com.
